WANG Jing, LI Fengjuan, ZHANG Huapeng, et al. Study on Protective Effects of Glycyrrhiza and Pueraria Fermentation Composition on Rats with Chronic Liver Injury[J]. Science and Technology of Food Industry, 2022, 43(12): 369−376. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2021110140.
Citation: WANG Jing, LI Fengjuan, ZHANG Huapeng, et al. Study on Protective Effects of Glycyrrhiza and Pueraria Fermentation Composition on Rats with Chronic Liver Injury[J]. Science and Technology of Food Industry, 2022, 43(12): 369−376. (in Chinese with English abstract). doi: 10.13386/j.issn1002-0306.2021110140.

Study on Protective Effects of Glycyrrhiza and Pueraria Fermentation Composition on Rats with Chronic Liver Injury

More Information
  • Received Date: November 14, 2021
  • Available Online: April 14, 2022
  • Objective: To study the protective effect and potential mechanism of glycyrrhiza and pueraria fermentation composition on chronic liver injury induced by carbon tetrachloride (CCl4). Methods: SD rats were intragastric with normal saline, Diammonium Glycyrrhizinate Capsules (GLX) and glycyrrhiza and pueraria fermentation composition, respectively, and treated with carbon tetrachloride to establish chronic liver injury model. The contents of liver function indexes (ALT, AST, TBIL, TP), liver fiber indexes (PLD, TGF-β1, HA), endotoxin and inflammatory factors (LPS, TNF-α, IL-6) in serum of mice were detected by enzyme linked immunosorbent assay. Pathological changes of liver tissue were observed by light microscope and transmission electron microscope. At the same time, the intestinal flora of different treatment groups was quantitatively analyzed. Results: Compared with normal saline treatment group, treatment group glycyrrhiza and pueraria fermentation composition mice serum AST, ALT level decreased extremely significant (P<0.01). There were no significant differences in serum TBIL and TP levels in glycyrrhiza and pueraria fermentation composition treatment group before and after modeling. The results of liver fibrosis index showed that TGF-β1 (P<0.01), PLD (P<0.01) and HA (P<0.05) in glycyrrhiza and pueraria fermentation composition protected group were significantly lower than those in normal saline control group. Compared with normal saline treatment group, there were no significant differences in serum IL-6 and LPS levels before and after modeling in glycyrrhiza and pueraria fermentation composition treatment group, while TNF-α level extremely significant decreased in glycyrrhiza and pueraria fermentation composition treatment group (P<0.01). Pathological observation showed that there were no obvious pathological changes in liver tissues in glycyrrhiza and pueraria fermentation composition and GLX treatment groups. The number of EMB, EC, KV and CD in glycyrrhiza and pueraria fermentation composition protection group decreased, while TPY and MRS increased. Conclusion: Glycyrrhiza and pueraria fermentation composition and GLX had certain protective effects on chronic liver injury induced by CCl4 in rats, and glycyrrhiza and pueraria fermentation composition had more significant effects on liver fibrosis, reducing inflammation and endotoxin levels, and regulating intestinal flora during chronic liver injury.
  • [1]
    李冀, 李想, 曹明明, 等. 甘草药理作用及药对配伍比例研究进展[J]. 上海中医药杂志,2019,53(7):83−87. [LI Ji, LI Xiang, CAO Mingming, et al. Research progress in pharmacological actions of liquorice and proportion of couplet medicines in combination[J]. Shanghai Journal of Traditional Chinese Medicine,2019,53(7):83−87.

    LI Ji, LI Xiang, CAO Mingming, et al. Research progress in pharmacological actions of liquorice and proportion of couplet medicines in combination[J]. Shanghai Journal of Traditional Chinese Medicine, 2019, 53(7): 83-87.
    [2]
    甘草酸制剂肝病临床应用专家共识[J]. 临床肝胆病杂志, 2016, 32(5): 844−852.

    Expert consensus on clinical application of glycyrrhizin preparation in the treatment of liver diseases[J]. J Clin Hepatol, 2016, 32(5): 844−852.
    [3]
    史晨旭, 杜佳蓉, 吴威, 等. 葛根化学成分及药理作用研究进展[J]. 中国现代中药,2021,23(12):2177−2195. [SHI Chenxu, DU Jiarong, WU Wei, et al. Advances in the study of chemical constituents and pharmacological action of Puerariae lobatae radix[J]. Modern Chinese Medicine,2021,23(12):2177−2195.

    SHI Chenxu, DU Jiarong, WU Wei, et al. Advances in the study of chemical constituents and pharmacological action of Puerariae lobatae radix[J]. Modern Chinese Medicine, 2021, 23(12): 2177-2195.
    [4]
    木盼盼, 安琪, 张彦昭, 等. 一测多评法测定葛根药材中9个异黄酮成分的含量[J]. 中国中药杂志,2019,44(22):4888−4895. [MU Panpan, AN Qi, ZHANG Yanzhao, et al. Determination of 9 isoflavonoids in Puerariae lobatae radix with quantitative analysis of multi-components by single marker[J]. China Journal of Chinese Materia Medica,2019,44(22):4888−4895.

    MU Panpan, AN Qi, ZHANG Yanzhao, et al. Determination of 9 isoflavonoids in Puerariae lobatae radix with quantitative analysis of multi-components by single marker[J]. China Journal of Chinese Materia Medica, 2019, 44(22) : 4888-4895.
    [5]
    赵月蓉, 侯碧玉, 张莉, 等. 葛根素对实验性肝损伤的治疗作用研究进展[J]. 中国新药杂志,2017,26(9):1005−1010. [ZHAO Yuerong, HOU Biyu, ZHANG Li, et al. Research progress of puerarin in the treatment of experimental liver injury[J]. Chinese Journal of New Drugs,2017,26(9):1005−1010.

    ZHAO Yuerong, HOU Biyu, ZHANG Li, et al. Research progress of puerarin in the treatment of experimental liver injury[J]. Chinese Journal of New Drugs, 2017, 26(9): 1005-1010.
    [6]
    朱振元, 罗游, 薛婧, 等. 葛根功能饮料的急性毒性及解酒护肝功效评价[J]. 食品研究与开发,2016,37(21):160−163. [ZHU Zhenyuan, LUO You, XUE Jing, et al. Acute toxicity test and sober and hepatoproctive efficacy evaluation of radix puerariae functional beverage[J]. Food Research and Development,2016,37(21):160−163. doi: 10.3969/j.issn.1005-6521.2016.21.037

    ZHU Zhenyuan, LUO You, XUE Jing, et al. Acute toxicity test and sober and hepatoproctive efficacy evaluation of radix puerariae functional beverage[J]. Food Research and Development, 2016, 37(21): 160-163. doi: 10.3969/j.issn.1005-6521.2016.21.037
    [7]
    KAI M C, STEFANIE A, CHRISTIAN T. Role of bile acids in the gut-liver axis[J]. Journal of Hepatology,2018,68(5):1083−1085. doi: 10.1016/j.jhep.2017.11.025
    [8]
    WANG Rui, TANG Ruqi, LI Bo, et al. Gut microbiome, liver immunology, and liver diseases[J]. Cellular & Molecular Immunology,2021(8):4−17.
    [9]
    ANUPRIYA T, JUSTINE D, DAVID A B, et al. The gut-liver axis and the intersection with the microbiome[J]. Nature Reviews Gastroenterology & Hepatology,2018,15:397−411.
    [10]
    SIDDHARTHA S G, WANG J, PAUL J Y, et al. Intestinal barrier function and metabolic/liver diseases[J]. Liver Research,2020(4):81−87.
    [11]
    RYO A. Commensal microbe-derived acetate suppresses NAFLD/NASH development via hepatic FFAR2 signalling in mice[J]. Microbiome,2021,9(1):188. doi: 10.1186/s40168-021-01125-7
    [12]
    SHARPTON S, SCHNABL B, KNIGHT R, et al. Current concepts, opportunities and challenges of gut microbiome-based personalized medicine in nonalcoholic fatty liver disease[J]. Cell Metabolism,2011,33(1):21−32.
    [13]
    孟凡涛, 刘冬菊. 研究中药发酵炮制法[J]. 世界最新医学信息文摘,2018,18(10):8−9. [MENG Fantao, LIU Dongju. To study the method of fermentation of Chinese medicine[J]. World Latest Medicine Informationn (Electronic Version),2018,18(10):8−9.

    MENG Fantao, LIU Dongju. To study the method of fermentation of Chinese medicine[J]. World Latest Medicine Informationn (Electronic Version), 2018, 18(10): 8-9.
    [14]
    李艳凤, 翟梦颖, 李雨昕, 王等. 发酵法在中药研究中的应用[J]. 医学综述,2020,26(4):753−757. [LI Yanfeng, ZHAI Mengying, LI Yuxin, et al. Application of fermentation method in study of traditional Chinese medicine[J]. Medical Recapitulate,2020,26(4):753−757. doi: 10.3969/j.issn.1006-2084.2020.04.025

    LI Yanfeng, ZHAI Mengying, LI Yuxin, et al. Application of fermentation method in study of traditional Chinese medicine[J]. Medical Recapitulate, 2020, 26(4): 753-757. doi: 10.3969/j.issn.1006-2084.2020.04.025
    [15]
    张丽霞, 高文远, 王海洋. 微生物技术在中药炮制中的应用[J]. 中国中药杂志,2012,37(24):3695−3699. [ZHANG Lixia, GAO Wenyuan, WANG Haiyang. Application of microbial technology in the processing of traditional[J]. Chinese Medicine China Journal of Chinese Materia Medica,2012,37(24):3695−3699.

    ZHANG Lixia, GAO Wenyuan, WANG Haiyang. Application of microbial technology in the processing of traditional[J]. Chinese Medicine China Journal of Chinese Materia Medica, 2012, 37(24): 3695-3699.
    [16]
    彭静, 陈曦. 滨蒿内酯对四氯化碳致小鼠急性肝损伤的保护作用研究[J]. 中国药房,2021,32(2):231−235. [PENG Jing, CHEN Xi. Study on protective effects of scoparone on acute liver injury induced by CCl4 in mice[J]. China Pharmacy,2021,32(2):231−235. doi: 10.6039/j.issn.1001-0408.2021.02.18

    PENG Jing, CHEN Xi. Study on protective effects of scoparone on acute liver injury induced by CCl4 in mice[J]. China Pharmacy, 2021, 32(2): 231-235. doi: 10.6039/j.issn.1001-0408.2021.02.18
    [17]
    王昱. 红腹锦鸡肝脏结构的透射电镜观察[J]. 甘肃农业大学学报,2011,4:43−46. [WANG Yu. Transmission electron microscopical observation on the liver structure of Chroysolophus pictus[J]. Journal of Gansu Agricultural University,2011,4:43−46. doi: 10.3969/j.issn.1003-4315.2011.03.009

    WANG Yu. Transmission electron microscopical observation on the liver structure of Chroysolophus pictus[J]. Journal of Gansu Agricultural University, 2011, 4: 43-46. doi: 10.3969/j.issn.1003-4315.2011.03.009
    [18]
    刘旭凌, 杨广越, 张玮, 等. 桃红四物汤对CCl4诱导肝纤维化小鼠模型的干预作用及其机制[J]. 临床肝胆病杂志,2021,37(11):2563−2568. [LIU Xuling, YANG Guangyue, ZHANG Wei, et al. Therapeutic effect of Taohong Siwu decoction on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism[J]. J Clin Hepatol,2021,37(11):2563−2568. doi: 10.3969/j.issn.1001-5256.2021.11.016

    LIU Xuling, YANG Guangyue, ZHANG Wei, et al. Therapeutic effect of Taohong Siwu decoction on a mouse model of carbon tetrachloride-induced liver fibrosis and its mechanism[J]. J Clin Hepatol, 2021, 37(11). doi: 10.3969/j.issn.1001-5256.2021.11.016
    [19]
    张燕, 范晓翔, 章美武, 等. NLRC5 调节转化生长因子-β1诱导的肝星状细胞活化及逆转对肝纤维化的影响[J]. 中国全科医学,2020,23(24):3051−3059. [ZHANG Yan, FAN Xiaoxiang, ZHANG Meiwu, et al. Role of NLRC5 in the activation of hepatic stellate cells induced by TGF-β1 and reversal of hepatic fibrosis[J]. Chinese General Practice,2020,23(24):3051−3059.

    ZHANG Yan, FAN Xiaoxiang, ZHANG Meiwu, et al. Role of NLRC5 in the activation of hepatic stellate cells induced by TGF-β1 and reversal of hepatic fibrosis[J]. Chinese General Practice, 2020, 23(24): 3051-3059.
    [20]
    张永超, 毕研贞, 方萧, 等. 益生菌对慢加急性肝衰竭大鼠模型的保护作用及其机制[J]. 临床肝胆病杂志,2019,35(7):1570−1575. [ZHANG Yongchao, BI Yanzhen, FANG Xiao, et al. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. J Clin Hepatol,2019,35(7):1570−1575. doi: 10.3969/j.issn.1001-5256.2019.07.029

    ZHANG Yongchao, BI Yanzhen, FANG Xiao, et al. Protective effect of probiotics in rats with acute-on-chronic liver failure and related mechanism[J]. J Clin Hepatol, 2019, 35(7): 1570-1575. doi: 10.3969/j.issn.1001-5256.2019.07.029
    [21]
    JASMOHAN S B. Alcohol, liver disease and the gut microbiota[J]. Nature Reviews Gastroenterology & Hepatology,2019,16:235−246.
    [22]
    NAGA S B, PATRICK M G, JASMOHAN S B. Gut microbiome and liver disease[J]. Translational Research,2017,179:49−59. doi: 10.1016/j.trsl.2016.07.005
    [23]
    MING Lyu, WANG Yuefei. Balancing herbal medicine and functional food for prevention and treatment of cardiometabolic diseases through modulating gut microbiota[J]. Frontiers in Microbiology,2017,8:2146. doi: 10.3389/fmicb.2017.02146
    [24]
    LIN Tzulung, LU Chiachen, LAI Weifan, et al. Role of gut microbiota in identification of novel TCM-derived active metabolites[J]. Protein & Cell,2021,12:394−410.
    [25]
    LIU Meng, YUAN Jie, HU Wenjuan, et al. Pretreatment with broad-spectrum antibiotics alters the pharmacokinetics of major constituents of Shaoyao-Gancao decoction in rats after oral administration[J]. Pharmacologica Sinica,2019,40(2):288−296. doi: 10.1038/s41401-018-0011-0
    [26]
    LI Yun, LIU Tianyu, YAN Chen, et al. Diammonium glycyrrhizinate protects against non-alcoholic fatty liver disease in mice through modulation of gut microbiota and restoring intestinal barrier[J]. Molecular Pharmaceutics,2018,15(9):3860−3870. doi: 10.1021/acs.molpharmaceut.8b00347
    [27]
    ZHANG Feng, HE Fang, LI Li, et al. Bioavailability based on the gut microbiota: A new perspective[J]. Microbiology and Molecular Biology Reviews, 2020, 84(2):19.
  • Cited by

    Periodical cited type(13)

    1. 张莉,李桐,白茹,魏晓明,王梦倩,逄金柱,张智勇. 酵母发酵对挂面食用品质和消化特性的影响. 粮食与饲料工业. 2025(01): 57-61 .
    2. 王丹,李河,周松华,李会珍,侯天宇. 超高压预处理紫苏蛋白与大豆蛋白复配蛋白肉的工艺条件优化. 中国调味品. 2024(01): 18-24 .
    3. 张伟峰,黄泽华,王玉坤,张剑,赵萌萌,崔晚晚,安艳霞,殷贵鸿,周朋辉,赵阳. 复合菌发酵对非油炸方便面品质的影响. 食品科学. 2024(05): 210-216 .
    4. 刘安伟,吕莹果,邱学明,徐卫. 信阳手工挂面产业的现状与发展路径研究. 粮油科学与工程. 2024(02): 49-51 .
    5. 郭佳,刘翀,郑学玲. 醒发工艺对挂面品质及风味的影响. 食品与发酵工业. 2024(11): 247-255 .
    6. 杨园园,郇美丽,李桐,魏晓明,赵希雷,刘琪龙,宋燕燕,黄鑫蕾,张智勇,张毅,赵艺媛,解树珍. 不同厚度发酵挂面品质研究. 食品与发酵科技. 2024(05): 89-94+126 .
    7. 王文琪,王爱红,刘振海,陈恒均,黄玉军. 响应面优化乳酸菌发酵空心挂面制作工艺. 现代食品科技. 2024(09): 144-152 .
    8. 宁恒,马森,李力. 麦麸膳食纤维对发酵挂面品质的影响. 食品工业科技. 2023(18): 115-122 . 本站查看
    9. 徐蓓怡,王婧萱,李新宸,苏柯瑞,渠冰洁,张霞,梁赢,王金水. 酵母种类和发酵方式对冻融前后冷冻熟制空心面品质的影响. 食品研究与开发. 2023(17): 76-81 .
    10. 吴静仪,冯红,吕庆云,王学东,陈曦,蒋修军,万芳. 泡泡青蔬菜粉对面粉、面团性质影响及其挂面加工工艺优化. 食品工业科技. 2023(19): 244-251 . 本站查看
    11. 王纯,宫兆海,代福娟,操宇,刘君也,李志建. 不同种属酵母菌对发酵挂面品质的影响研究. 食品科技. 2023(10): 129-133+140 .
    12. 周慧超,刘翀,郑学玲. 添加不同粒度小麦颗粒粉对面团特性及挂面品质的影响. 食品与发酵工业. 2023(22): 86-93 .
    13. 权苗苗,许飞,陈洁,汪磊,谢亚敏,曹菲. 多菌种酵制多孔挂面的品质及风味物质分析. 河南工业大学学报(自然科学版). 2022(05): 53-60 .

    Other cited types(8)

Catalog

    Article Metrics

    Article views (165) PDF downloads (23) Cited by(21)

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return